GM1 - gangliosidosis, type 1 in the practice of a clinical laboratory diagnostics doctor
https://doi.org/10.31146/2949-4664-apps-2-3-40-44
Abstract
About the Authors
T. V. KonyukhovaRussian Federation
A. I. Mandzhieva
Russian Federation
E. V. Trukhina
Russian Federation
L. B. Guruleva
Russian Federation
References
1. Chevalier C., Detry G. Vacuolated lymphocytes and abnormal eosinophils in GM1 gangliosidosis, type 1. Br J Haematol. 2012 Feb;156(3):293. doi: 10.1111/j.1365-2141.2011.08929.x.
2. Gitzelmann R., Spycher M.A., Adank S. et al. Anomalous eosinophil granulocytes in blood and bone marrow: a diagnostic marker for infantile GM1-gangliosidosis? Eur J Pediatr. 1985 May;144(1):82-4. doi: 10.1007/BF00491934.
3. Salama R., Zhou J. Vacuolated lymphocytes signifying a metabolic disorder in an infant with developmental delay. Clin Case Rep. 2015 Nov 19;4(1):99-100. doi: 10.1002/ccr3.447.
4. Landing B.H., Silverman F.N., Craig J.M. et al. Familial neurovisceral lipidosis. An analysis of eight cases of a syndrome previously reported as “Hurler-variant,” “pseudo-Hurler,” and “Tay-Sachs disease with visceral involvement”. Am J Dis Child. 1964 Nov;108:503-22. PMID: 14209687.
5. Sinigerska I., Chandler D., Vaghjiani V. et al. Founder mutation causing infantile GM1-gangliosidosis in the Gypsy population. Mol Genet Metab. 2006 May;88(1):93-5. doi: 10.1016/j.ymgme.2005.12.009.
6. Brunetti-Pierri N., Scaglia F. GM1 gangliosidosis: review of clinical, molecular, and therapeutic aspects. Mol Genet Metab. 2008 Aug;94(4):391-396. doi: 10.1016/j.ymgme.2008.04.012.
7. Lang F.M., Korner P., Harnett M. et al. The natural history of Type 1 infantile GM1 gangliosidosis: A literature-based meta-analysis. Mol Genet Metab. 2020 Mar;129(3):228-235. doi: 10.1016/ j.ymgme.2019.12.012.
8. Lee J.S., Choi J.M., Lee M. et al. Diagnostic challenge for the rare lysosomal storage disease: Late infantile GM1 gangliosidosis. Brain Dev. 2018 May;40(5):383-390. doi: 10.1016/j.braindev.2018.01.009.
9. Regier D.S., Proia R.L., D’Azzo A. et al. The GM1 and GM2 Gangliosidoses: Natural History and Progress toward Therapy. Pediatr Endocrinol Rev. 2016 Jun;13 Suppl 1(Suppl 1):663-73. PMID: 27491214; PMCID: PMC8186028.
10. Patterson M.C. Gangliosidoses. Handb Clin Neurol. 2013;113:1707-8. doi: 10.1016/B978-0-444-59565-2.00039-3.
11. Su P., Khaledi H., Waggoner C. et al. Detection of GM1-gangliosidosis in newborn dried blood spots by enzyme activity and biomarker assays using tandem mass spectrometry. J Inherit Metab Dis. 2021 Jan;44(1):264-271. doi: 10.1002/jimd.12269.
12. Erol I., Alehan F., Pourbagher M.A. et al. Neuroimaging findings in infantile GM1 gangliosidosis. Eur J Paediatr Neurol. 2006 Sep-Nov;10(5-6):245-8. doi: 10.1016/j.ejpn.2006.08.005.
13. Caciotti A., Garman S.C., Rivera-Colón Y. et al. GM1 gangliosidosis and Morquio B disease: an update on genetic alterations and clinical findings. Biochim Biophys Acta. 2011 Jul;1812(7):782-90. doi: 10.1016/j.bbadis.2011.03.018.
14. Rha A.K., Maguire A.S., Martin D.R. GM1 Gangliosidosis: Mechanisms and Management. Appl Clin Genet. 2021 Apr 9; 14:209-233. doi: 10.2147/TACG.S206076.
Review
For citations:
Konyukhova T.V., Mandzhieva A.I., Trukhina E.V., Guruleva L.B. GM1 - gangliosidosis, type 1 in the practice of a clinical laboratory diagnostics doctor. Archives of Pediatrics and Pediatric Surgery. 2024;2(3):40-44. (In Russ.) https://doi.org/10.31146/2949-4664-apps-2-3-40-44